|
1) Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982; 51: 189-99
|
|
|
|
2) Zeng W, Nakao S, Takamatsu H, et al. Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. Blood. 1999; 93: 3008-16
|
|
|
|
|
|
3) Molldrem JJ, Jiang YZ, Stetler-Stevenson M, et al. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor V beta profiles. Br J Haematol. 1998; 102: 1314-22
|
|
|
|
|
4) Ishikawa T, Tohyama K, Nakao S, et al. A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: Presence of CD55-CD59- blood cells predicts platelet response. Int J Hematol. 2007; 86: 150-7
|
|
|
|
|
5) Wang H, Chuhjo T, Yasue S, et al. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood. 2002; 100: 3897-902
|
|
|
|
|
|
6) Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006; 107: 1308-14
|
|
|
|
|
|
7) Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-88
|
|
|
|
|
|
8) Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999; 17: 3835-49
|
|
|
|
|
|
9) Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008; 26: 2505-11
|
|
|
|
|
|
10) Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia. 2007; 21: 1436-41
|
|
|
|
|
|
11) Dixit A, Chatterjee T, Mishra P, et al. Cyclosporin A in myelodysplastic syndrome: a preliminary report. Ann Hematol. 2005; 84: 565-8
|
|
|
|
|
|
12) Chen S, Jiang B, Da W, et al. Treatment of myelodysplastic syndrome with cyclosporin A. Int J Hematol. 2007; 85: 11-7
|
|
|
|
|
|
13) Atoyebi W, Bywater L, Rawlings L, et al. Treatment of myelodysplasia with oral cyclosporin. Clin Lab Haematol. 2002; 24: 211-4
|
|
|
|
|
|
14) Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol. 1998; 100: 304-9
|
|
|
|
|
|
15) Matsuda A, Germing U, Jinnai I, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood. 2005; 106: 2633-40
|
|
|
|
|
|
16) Stadler M, Germing U, Kliche KO, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia. 2004; 18: 460-5
|
|
|
|
|
|
17) Yoshimi A, Baumann I, Fuhrer M, et al. Immunosuppressive therapy with anti-thymocyte globulin and cyclosporine A in selected children with hypoplastic refractory cytopenia. Haematologica. 2007; 92: 397-400
|
|
|
|
|
|
18) Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002; 100: 1570-4
|
|
|
|
|
|
19) Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 2003; 102: 3025-7
|
|
|
|
|
|
20) Sugimori C, Yamazaki H, Feng X, et al. Roles of DRB1 ＊1501 and DRB1 ＊1502 in the pathogenesis of aplastic anemia. Exp Hematol. 2007; 35: 13-20
|
|
|
|
|
|
21) Wang SA, Pozdnyakova O, Jorgensen JL, et al. Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats. Haematologica. 2009; 94: 29-37
|
|
|
|
|
|
22) Shimamoto T, Iguchi T, Ando K, et al. Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements. Br J Haematol. 2001; 114: 358-61
|
|
|
|
|
|
23) List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355: 1456-65
|
|
|
|
|
|
24) Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008; 111: 86-93
|
|
|
|
|
|
25) Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006; 24: 3895-903
|
|
|
|
|